Wang S - Search Results

1

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

McCalmont H, Li KL, Jones L, Toubia J, Bray SC, Casolari DA, Mayoh C, Samaraweera SE, Lewis ID, Prinjha RK, Smithers N, Wang S, Lock RB, D'Andrea RJ. McCalmont H, et al. Among authors: wang s. Blood Adv. 2020 Jan 28;4(2):296-300. doi: 10.1182/bloodadvances.2019000586. Blood Adv. 2020. PMID: 31971998 Free PMC article.

2

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.

Teo T, Lam F, Yu M, Yang Y, Basnet SK, Albrecht H, Sykes MJ, Wang S. Teo T, et al. Among authors: wang s. Mol Pharmacol. 2015 Aug;88(2):380-9. doi: 10.1124/mol.115.098012. Epub 2015 Jun 4. Mol Pharmacol. 2015. PMID: 26044548

3

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Among authors: wang s. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

4

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, Noll B, Milne R, Peng J, Wang S. Rahaman MH, et al. Among authors: wang s. Invest New Drugs. 2019 Aug;37(4):625-635. doi: 10.1007/s10637-018-0661-2. Epub 2018 Sep 8. Invest New Drugs. 2019. PMID: 30194564

5

Targeting CDK9 for treatment of colorectal cancer.

Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S. Rahaman MH, et al. Among authors: wang s. Mol Oncol. 2019 Oct;13(10):2178-2193. doi: 10.1002/1878-0261.12559. Epub 2019 Aug 21. Mol Oncol. 2019. PMID: 31398271 Free PMC article.

6

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, Wang S. Diab S, et al. Among authors: wang s. ChemMedChem. 2014 May;9(5):962-72. doi: 10.1002/cmdc.201300552. Epub 2014 Feb 12. ChemMedChem. 2014. PMID: 24677692

7

Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.

Yu M, Li P, Basnet SK, Kumarasiri M, Diab S, Teo T, Albrecht H, Wang S. Yu M, et al. Among authors: wang s. Eur J Med Chem. 2015 May 5;95:116-26. doi: 10.1016/j.ejmech.2015.03.032. Epub 2015 Mar 17. Eur J Med Chem. 2015. PMID: 25800647

8

Targeting CDK6 in cancer: State of the art and new insights.

Tadesse S, Yu M, Kumarasiri M, Le BT, Wang S. Tadesse S, et al. Among authors: wang s. Cell Cycle. 2015;14(20):3220-30. doi: 10.1080/15384101.2015.1084445. Cell Cycle. 2015. PMID: 26315616 Free PMC article. Review.

9

Unveiling new chemical scaffolds as Mnk inhibitors.

Diab S, Li P, Basnet SK, Lu J, Yu M, Albrecht H, Milne RW, Wang S. Diab S, et al. Among authors: wang s. Future Med Chem. 2016;8(3):271-85. doi: 10.4155/fmc.15.190. Epub 2016 Feb 24. Future Med Chem. 2016. PMID: 26910782

10

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.

Li P, Diab S, Yu M, Adams J, Islam S, Basnet SK, Albrecht H, Milne R, Wang S. Li P, et al. Among authors: wang s. Oncotarget. 2016 Aug 30;7(35):56811-56825. doi: 10.18632/oncotarget.10796. Oncotarget. 2016. PMID: 27462781 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109,888 results

Search Page